APPLICATION
NDA012223
TYPE
NDA
ORIGINAL APPROVAL
1960-06-28
LATEST ACTION
2018-11-23
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued
Products
AQUAMEPHYTON · ReferenceDiscontinued
PHYTONADIONE 1MG/0.5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE · INJECTION
AQUAMEPHYTON · ReferenceDiscontinued
PHYTONADIONE 10MG/ML ***Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE · INJECTION
Approval history
2001-08-16Manufacturing (CMC) · Supplement 37 · standardAP
1998-07-14Manufacturing (CMC) · Supplement 35 · standardAP
1998-05-28Manufacturing (CMC) · Supplement 34 · standardAP
1997-01-14Manufacturing (CMC) · Supplement 33 · standardAP
1996-12-06Manufacturing (CMC) · Supplement 32 · standardAP
1996-12-06Manufacturing (CMC) · Supplement 31 · standardAP
1996-06-25Manufacturing (CMC) · Supplement 30 · standardAP
1995-12-05Manufacturing (CMC) · Supplement 29 · standardAP
1995-06-08Manufacturing (CMC) · Supplement 28 · standardAP
1995-04-24Labeling · Supplement 27 · standardAP
1991-06-28Labeling · Supplement 26AP
1990-04-26Labeling · Supplement 25AP
1986-08-19Labeling · Supplement 21AP
1985-08-27Manufacturing (CMC) · Supplement 24 · standardAP
1984-10-11Manufacturing (CMC) · Supplement 23 · standardAP
1982-08-18Labeling · Supplement 22AP
1981-11-03Manufacturing (CMC) · Supplement 19 · standardAP
1981-07-14Manufacturing (CMC) · Supplement 20 · standardAP
1980-11-28Manufacturing (CMC) · Supplement 18 · standardAP
1979-09-18Manufacturing (CMC) · Supplement 17 · standardAP
1976-09-01Manufacturing (CMC) · Supplement 16 · standardAP
1960-06-28Type 5 - New Formulation or New Manufacturer · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.